AGENUS INC Additional Paid in Capital
AGENUS INC (AGEN) had Additional Paid in Capital of $1.95 billion as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-07
- 2026-06-30: Additional Paid in Capital $1.95B.
- 2026-03-31: Additional Paid in Capital $1.92B.
- 2025-12-31: Additional Paid in Capital $1.91B.
- 2025-09-30: Additional Paid in Capital $1.90B.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $1.95B 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $1.92B 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $1.91B 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $1.90B 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $1.88B 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $1.87B 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $1.86B 10-K · filed 2026-03-16 | |
| 2024-09-30 | $1.85B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.83B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.82B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $1.80B 10-K · filed 2025-03-17 | $1.79B 10-K · filed 2024-03-14 |
| 2023-09-30 | $1.78B 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $1.75B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $1.72B 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $1.64B 10-K · filed 2024-03-14 | |
| 2022-09-30 | $1.61B 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $1.58B 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $1.55B 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.52B 10-K · filed 2023-03-16 | |
| 2021-09-30 | $1.46B 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.35B 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $1.33B 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $1.26B 10-K · filed 2022-03-01 | |
| 2020-09-30 | $1.23B 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $1.16B 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $1.13B 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $1.06B 10-K · filed 2021-03-16 | |
| 2019-09-30 | $1.06B 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $1.05B 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $1.04B 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $1.01B 10-K · filed 2020-03-16 | $1.01B 10-K · filed 2019-03-18 |
| 2018-09-30 | $999.58M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $984.19M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $960.05M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $951.81M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $940.91M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $938.41M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $933.22M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $866.85M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $858.85M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $856.11M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $856.07M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $851.10M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $841.04M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $837.46M 10-Q · filed 2015-08-03 | |
| 2015-03-31 | $756.80M 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $715.67M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $714.73M 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $714.09M 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $711.63M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $644.57M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $640.41M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $618.77M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $596.66M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $595.92M 10-K · filed 2014-03-07 | |
| 2012-09-30 | $594.92M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $591.00M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $584.81M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $581.39M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $585.71M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $578.17M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $569.85M 10-K · filed 2012-03-06 | $568.92M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |